Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment

 

 

 

Emcitate®

Our lead product candidate

Pipeline

General Corporate presentation

Press Releases

August 30, 2022

Egetis to participate at upcoming medical conferences

Read more

August 23, 2022

Egetis to participate at upcoming investor conferences

Read more

Regulatory

August 19, 2022

Interim report Q2 2022

Read more

Upcoming event

October 13, 2022

Capital Markets Day (link to registration)

Latest presentation

August 22, 2022

Egetis' Corporate Presentation

Latest Report

August 19, 2022

Q2 Report 2022

Calendar and upcoming reports

October 13, 2022

Capital Markets Day

November 8, 2022

Interim report January - September

November 21-23, 2022

SEB Life Science Summit

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com

Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies. However, you may visit "Settings" to provide a controlled consent. Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all